Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.81 ▼ -0.03
(-3.13%)
MKT CAP: $36.0M • VOL: 56.0K
52W L $1 52W H $1
ELUT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $12.3M | $14.5M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $6.6M | $6.7M | — |
| Gross Margin % | 53.7% | 46.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$26.9M | -$30.7M | -$30.5M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | $53.4M | -$53.9M | -$37.7M |
| EBITDA (Normalized) | -$25.4M | -$30.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$44.8M | -$22.7M | -$21.8M |
| Capital Expenditures (CapEx) | $1.9M | $654.0K | — |
| Free Cash Flow (FCF) | -$46.7M | -$23.3M | -$21.8M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $36.4M | $13.2M | — |
| Total Debt (Short + Long Term) | — | $22.6M | — |
| Total Stockholders' Equity | $27.7M | -$46.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELUT.